secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMPEL PHARMACEUTICALS INC (—)
CIK:        0001445499
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0001193125-23-299243
Event type: m_and_a
Sentiment:  negative
Materiality: 0.95
Item codes: 1.01, 1.03, 2.04, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Impel Pharmaceuticals files Chapter 11, enters $17.5M stalking horse asset sale with JN Bidco
--------------------------------------------------------------------------------

- Filed Chapter 11 on Dec 19, 2023 in N.D. Texas; will operate as debtor-in-possession while seeking court-approved sale.
- Stalking horse asset purchase agreement with JN Bidco LLC for $17.5M cash plus potential contingent earn-out based on future net sales and licensing fees.
- Appointed Brandon Smith (Teneo Capital) as Chief Restructuring Officer to oversee restructuring and sale process.
- Reduced workforce by ~53% (39 employees) effective Dec 15, 2023; retains ~34 employees to continue operations during Chapter 11.
- Credit facility under Oaktree automatically accelerated upon filing; enforcement stayed by bankruptcy proceedings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445499/000119312523299243/0001193125-23-299243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445499/000119312523299243/d676211d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-299243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer